US Congress Extends Rare Pediatric Disease Voucher Program to 2029, Boosting Neuren’s Prospects

• Rare Pediatric Disease Priority Review Voucher program extended to 30 September 2029
• Neuren holds designations for three rare pediatric diseases with its drug NNZ-2591
• FDA approval of NNZ-2591 could earn Neuren a valuable priority review voucher
• Vouchers can be sold or used for expedited FDA review, with recent sales reaching US$200 million